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Abstract The concentrative pyrimidine-preferring nucleoside
transporter 1 (hCNT1), cloned from human fetal liver, was
expressed in Xenopus laevis oocytes. Using the two-electrode
voltage-clamp technique, it is shown that translocation of
nucleosides by this transporter generates sodium inward currents.
Membrane hyperpolarization (from 350 to 3150 mV) did not
affect the K0:5 for uridine, although it increased the transport
current approximately 3-fold. Gemcitabine (a pyrimidine nucleo-
side-derived drug) but not fludarabine (a purine nucleoside-
derived drug) induced currents in oocytes expressing the hCNT1
transporter. The K0:5 value for gemcitabine at 350 mV
membrane potential was lower than that for natural substrates,
although this drug induced a lower current than uridine and
cytidine, thus suggesting that the affinity binding of the drug
transporter is high but that translocation occurs more slowly.
The analysis of the currents generated by the hCNT1-mediated
transport of nucleoside-derived drugs used in anticancer and
antiviral therapies will be useful in the characterization of the
pharmacological profile of this family of drug transporters and
will allow rapid screening for uptake of newly developed
nucleoside-derived drugs. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Most nucleoside-derived drugs used in antiviral and anti-
cancer therapies may be substrates of one or more of the
cloned CNT and ENT transporters [1^4]. Two ENT trans-
porter isoforms have been cloned, ENT1 and ENT2. The
former is inhibited by nanomolar concentrations of the nu-
cleoside analog NBTI whereas the latter is insensitive to this
inhibitor. The two ENT isoforms identi¢ed so far show broad
substrate speci¢city and appear to mediate equilibrative trans-
location of nucleosides across the plasma membrane with rel-
atively low a⁄nity [1^4]. Similarly, two CNT isoforms have
been cloned, CNT1 which is pyrimidine-preferring and CNT2
which is purine-preferring [1^4]. Heterologous expression of
these membrane proteins in mammalian cells and Xenopus
laevis oocytes has recently been used to determine the phar-
macological pro¢le of the CNT and ENT transporters, by
measuring either the in£ux of radiolabeled substrates or the
interaction with the carrier by inhibition of the uptake of the
natural substrate [2^9]. The ¢rst approach is direct but re-
quires a labeled drug and is time-consuming, which may not
be suitable for pharmacological screenings. The second ap-
proach, in contrast, does not de¢ne the substrate speci¢city
of the carrier. Since CNT transporters are Na-dependent, the
coupling of Na in£ux with nucleoside uptake should induce
measurable currents which may facilitate an electrophysiolog-
ical approach to the pharmacological properties of these rel-
atively new family of drug transporters. Previous evidence
suggests that nucleoside transport through these systems is
dependent on the transmembrane electrical gradient and
may be consistent with a stoichiometry of one nucleoside
per sodium ion being cotransported [10,11].
In this report, it is shown that human nucleoside transport-
er 1 (hCNT1) expression in X. laevis oocytes results in the
induction of currents due to the cotransport of sodium with
some nucleosides. The substrate speci¢city is that expected for
a pyrimidine-preferring transporter. The evidence that CNT-
related activity can be measured electrophysiologically opens
the possibility for massive screening for transporter speci¢city
of nucleoside derivatives suitable for the treatment of a variety
of human viral and neoplastic diseases.
2. Materials and methods
2.1. Cloning of the hCNT1 cDNA
The hCNT1 clone was obtained by ampli¢cation of an oligo(dT)-
primed cDNA library from human fetal liver (Marathon Ready
cDNA, Clontech), using a PCR approach with Advantage 2 Polymer-
ase Mix (Clontech). Primers HC1E (5P-GCTGCACTGCATG-
GTTGCTGCTGGATGTGTTG-3P) and HC1D (5P-GGGAAGGGG-
CATGTGAGGGACCCCAGGAGA-3P), derived from the reported
sequence for hCNT1 (GenBank1 accession number U62966), were
used in a touchdown PCR that produced a unique DNA band with
an approximate molecular weight of 2 kb. This PCR product was gel-
puri¢ed, used in an additional reaction of dATP added to the 3P end
with TaqPolymerase (Promega), again puri¢ed by a DNA clean up
column (Wizard DNA Cleanup System, Promega) and ¢nally ligated
to the plasmid pGEM-Teasy (pGEM-Teasy Vector System II, Prom-
ega) with T4 DNA ligase (New England Biolabs). The construct
pGEMT-hCNT1 after both strands Taq DyeDeoxy terminator cycle
sequencing (DNA sequencing kit, dRhodamine Terminator Cycle Se-
quencing, Perkin Elmer) and aligned with a published sequence pre-
viously described, con¢rmed the nature of the hCNT1 cDNA. The
hCNT1 cDNA was then inserted into the pBSII(KS) vector, which
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contained a poly-A tail of 54 bp from the original plasmid pBSII(KS)-
hSGLT1 [12] as follows. pBSII(KS)-hSGLT1 was digested with NsiI,
blunted with Klenow fragment, puri¢ed through a DNA clean up
column, digested with SalI and gel-puri¢ed. The construct pGEMT-
hCNT1 was digested in parallel. The two fragments were ligated with
T4 DNA ligase as previously described and the product, pBSII(KS)-
hCNT1-poly-A tail, was used to transform Escherichia coli XL-1 Blue.
Plasmid pBSII(KS)-hSGLT1 was kindly donated by Dr. E.M. Wright
(UCLA).
2.2. Expression of hCNT1 in Xenopus oocytes
The plasmid containing the hCNT1 cDNA was linearized with XbaI
and cRNA synthesized using the Ambion T3 MEGAscript kit (Aus-
tin, TX, USA) in the presence of m7G(5P)ppp(5P)G. 50 ng of cRNA
was injected into X. laevis oocytes as previously described [13] and
maintained at 18‡C in Barth’s medium for 3^5 days. Uridine uptake
assays were performed by a radiotracer method [14]. Brie£y, groups of
6^10 oocytes were incubated for 1 h at room temperature in 400 Wl of
Na bu¡er containing 50 WM [3H]uridine (3 WCi/ml, speci¢c activity
36.0 Ci/mmol) (Amersham Pharmacia Biotech, Buckinghamshire,
UK), either in the absence or in the presence of nucleosides at the
indicated concentrations. After the incubation period had elapsed, the
3H content of each oocyte was determined by liquid scintillation
counting. Uptakes are expressed as pmol/h per oocyte.
Electrophysiology experiments were performed to examine sub-
strate-induced Na inward currents using the two-electrode voltage-
clamp method [15]. The oocyte membrane potential (Vm) was held at
350 mV and continuous current data were recorded using Axoscope
V3. To obtain current/voltage ratios, 11 pulses of potential between
+50 and 3150 mV in 20 mV decrements were applied for 100 ms,
using pClamp 6 software (both from Axon Instruments, Foster City,
CA, USA).
The apparent a⁄nity constant (K0:5) and the maximal current for
saturating uridine (Imax) were obtained by ¢tting the steady-state cur-
rents at each membrane potential to the equation:
I  ImaxWS=K0:5  S;
where [S] is the substrate concentration, using the non-linear ¢tting
method in SigmaPlot 4 (SPSS, Chicago, IL, USA).
In the experiments performed in the absence of sodium, NaCl was
replaced by choline Cl.
All the nucleosides used in these experiments were purchased from
Sigma (St. Louis, MO, USA).
3. Results and discussion
Fig. 1 shows the inward currents evoked by saturating con-
centrations of natural nucleosides and nucleoside derivatives
used in cancer treatment in an oocyte clamped at 350 mV
expressing the hCNT1 transporter. Uridine, a common sub-
strate for hCNT1 and hCNT2, elicited the highest currents,
whereas cytidine, a pyrimidine which presumably is a hCNT1-
speci¢c substrate, induced Na inward currents which were
50% of those induced by uridine (Fig. 1; Table 1). Gemcita-
bine, a £uoropyrimidine currently used in the treatment of a
variety of solid tumors, including pancreatic cancer, also gen-
erated currents but with signi¢cantly lower intensity than the
natural substrates (Fig. 1; Table 1). This agrees with previous
£ux measurements of radiolabeled substrates performed on
Xenopus oocytes independently expressing the four nucleoside
transporters cloned so far. Formycin B and guanosine,
hCNT2-speci¢c substrates, did not evoke inward currents
(Fig. 1). Similarly, £udarabine, a nucleoside-derived drug cur-
rently used in the treatment of lymphoproliferative malignan-
cies, did not induce currents either. Fludarabine monophos-
phate was also checked as a putative substrate because this is
the chemical form of the prodrug administered to the patients.
Fig. 2. K0:5 and Imax for uridine as a function of membrane potential. Experiments were routinely performed in hCNT1 expressing oocytes,
3 days after cRNA injection. K0:5 and Imax were obtained at every membrane potential by ¢tting the steady-state current obtained at six di¡er-
ent concentrations of uridine (from 10 to 500 WM) to the equation in Section 2. A representative experiment using a single oocyte expressing
hCNT1 is shown. The error bars correspond to the error of the ¢tting. (A) K0:5/V curve. K0:5 values are very similar at each membrane poten-
tial between 350 mV and 3150 mV. (B) Imax/V. Maximal current increases with more negative potentials from 376 þ 3.5 nA at 350 mV to
3190 þ 15 nA at 3150 mV. Similar results were obtained with oocytes from two di¡erent frog donors.
Fig. 1. Na currents evoked by di¡erent nucleosides and nucleoside-
derived drugs in a single oocyte expressing hCNT1. Oocytes were
held at 350 mV and continuously perfused with Na bu¡er in the
absence of substrate (black box). The current registered under that
condition corresponds to the base-line current (20 nA). The addition
of nucleosides or derivatives (0.5 mM) is indicated by an arrow.
After perfusion with each nucleoside, oocytes were washed out in
Na-free medium (blank box). A representative result in a single
oocyte expressing hCNT1 is shown.
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As expected for a nucleotide, this compound did not induce
any currents in oocytes expressing hCNT1.
Data in Fig. 1 also show that the shift in inward current as
a result of sodium addition in oocytes expressing hCNT1 is
signi¢cant and much higher than the shift observed in control
oocytes (not shown). This observation suggests that there is a
slippage of the cation through the transporter, as previously
reported for other Na-dependent cotransporters like the Na/
glucose cotransporter SGLT1 [16].
Interestingly, addition of a hCNT1 substrate in the absence
of sodium also resulted in the induction of a small current
(not shown). For instance, 0.5 mM uridine in choline chloride
medium produced 20% of the current in NaCl medium at 350
mV membrane potential, which suggests that the transporter
is also coupled to an ion other than sodium. Studies are in
progress to determine which other ion(s) are involved in nu-
cleoside transport mediated by hCNT1.
Substrate-evoked currents at 350 mV membrane potential
were measured at increasing substrate concentrations. The
pattern followed Michaelis^Menten type saturation kinetics,
thus allowing the calculation of K0:5 values for uridine, gem-
citabine and cytidine (Table 1). hCNT1 shows higher a⁄nity
for the drug than for natural substrates but the intensity of
the current is much lower, suggesting that gemcitabine binds
better to the transporter but that translocation is lower. These
observations are in agreement with the apparent Km values
derived from £ux measurements recently performed by others
[9]. Similarly, a glucose derivative, indican (indoxyl-B-D-glu-
copyranoside), shows a much higher a⁄nity for SGLT1 than
the natural substrates but only generates 14% of the maximal
current [17], which suggests that increasing the size of the
conjugate reduces the turnover rate of the transporter
although its chemical structure favors the binding to the car-
rier.
In another set of experiments, the K0:5 for uridine was
shown to be largely independent of Vm, increasing only at
310 mV by nearly 2.5-fold (Fig. 2). However, Imax was volt-
age-dependent at hyperpolarized membrane potentials and did
not approach saturation at the membrane potential range
used. This suggests that agents that hyperpolarize the plasma
membrane also increase the transport rate mediated by
hCNT1. This evidence agrees with previous experiments using
isolated rat hepatocytes, in which it was shown that glucagon
and ionophores able to hyperpolarize the plasma membrane
induce a transient activation of Na-dependent nucleoside
transport into liver parenchymal cells [11]. Hepatocytes ex-
press at least CNT1 and CNT2, and their expression is known
to be regulated by cell di¡erentiation and transformation [18^
20]. In other cell types, such as human B-lymphocytes, acti-
vation is also associated with up-regulation of CNT activities
[21]. Since the pattern and activity of nucleoside transporters
appear to be regulated in mammalian cells and this may be a
putative mechanism by which cells develop resistance to anti-
cancer and antiviral treatments, we believe it was important to
set up a rapid method to establish the pharmacological pro¢le
of these transporters. Such a method is presented in this
study. As discussed above, measurement of £ux of radiola-
beled tracers is time-consuming and may be limited by the
availability of labeled drugs. Moreover, inhibition studies can-
not be reliable. As shown in Fig. 3, £udarabine, a nucleoside-
derived drug which, according to the present data, is not an
hCNT1 substrate, can inhibit uridine uptake in oocytes ex-
pressing the hCNT1 transporter, which suggests that there
might be interaction of certain nucleosides with transporters
at the plasma membrane, without substrate translocation.
In summary, this study provides the ¢rst electrophysiolog-
ical characterization of a nucleoside transporter, which is in-
volved in the uptake of £uoropyrimidines, such as gemcita-
bine, currently used in the treatment of solid tumors.
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